181.98
+1.23(+0.68%)
Currency In USD
| Previous Close | 180.75 |
| Open | 181.86 |
| Day High | 182.69 |
| Day Low | 179.27 |
| 52-Week High | 185.17 |
| 52-Week Low | 110.04 |
| Volume | 1.23M |
| Average Volume | 1.8M |
| Market Cap | 26.7B |
| PE | 16.59 |
| EPS | 10.97 |
| Moving Average 50 Days | 156.11 |
| Moving Average 200 Days | 138.01 |
| Change | 1.23 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $646.17 as of December 05, 2025 at a share price of $181.98. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $746.8 as of December 05, 2025 at a share price of $181.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BED
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
GlobeNewswire Inc.
Nov 28, 2025 12:30 AM GMT
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) --
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
GlobeNewswire Inc.
Nov 24, 2025 12:30 PM GMT
Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clin